Searched for: in-biosketch:true
person:tanejs01
Re: The Effect of a Pure Anti-Inflammatory Therapy on Reducing Prostate-Specific Antigen Levels in Patients Diagnosed with a Histologic Prostatitis
Taneja, Samir S
PMID: 27751452
ISSN: 1527-3792
CID: 2548522
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial
Taneja, Samir S
PMID: 27628795
ISSN: 1527-3792
CID: 2263912
Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer
Taneja, Samir S
PMID: 27628794
ISSN: 1527-3792
CID: 2263902
Re: Reevaluating PSA Testing Rates in the PLCO Trial
Taneja, Samir S
PMID: 27628793
ISSN: 1527-3792
CID: 2263892
Predictive Value of Negative 3T Multiparametric Prostate MRI on 12 Core Biopsy Results
Wysock, James S; Mendhiratta, Neil; Zattoni, Fabio; Meng, Xiaosong; Bjurlin, Marc; Huang, William C; Lepor, Herbert; Rosenkrantz, Andrew B; Taneja, Samir S
OBJECTIVES: To evaluate the cancer detection rates (CDR) for men undergoing 12 core systematic prostate biopsy with negative prebiopsy mpMRI (NegMR). MATERIALS & METHODS: Clinical data from consecutive men undergoing prostate biopsy with prebiopsy 3T mpMRI from December 2011 to August 2014 were reviewed from an IRB approved prospective database. Prebiopsy mpMRI was read by a single radiologist and men with NegMR prior to biopsy were identified for this analysis. Clinical features, CDR, and NPV rates were summarized. RESULTS: Seventy five men underwent SPB with a NegMRI during the study period. For the entire cohort, men with no prior biopsy, men with prior negative biopsy, and men enrolled in active surveillance protocols, overall CDR was 18.7%, 13.8%, 8.0% and 38.1%, respectively, and detection of Gleason sum >/= 7 (GS>/=7) cancer was 1.3%, 0%, 4.0% and 0%, respectively. The NPV for all cancers was 81.3%, 86.2%, 92.0%, and 61.9%, and for GS>/=7 cancer was 98.7%, 100%, 96.0% and 100%, respectively. CONCLUSIONS: Negative prebiopsy mpMRI confers an overall NPV of 82% on 12 core biopsy for all cancer and 98% for GS>/=7. Based upon biopsy indication, these findings assist in prebiopsy risk stratification for detection of high risk disease and may provide guidance in the decision to pursue biopsy
PMID: 26800439
ISSN: 1464-410x
CID: 1922342
Final Results of a Phase I/II Multicenter Trial of WST11 (TOOKAD(R) Soluble) Vascular-Targeted Photodynamic Therapy (VTP) for Hemiablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Conducted in the United States
Taneja, Samir S; Bennett, James; Coleman, Jonathan; Grubb, Robert; Andriole, Gerald; Reiter, Robert E; Marks, Leonard; Azzouzi, Abdel-Rahmene; Emberton, Mark
INTRODUCTION: Vascular targeted photodynamic therapy (VTP) with WST11 (TOOKAD(R) Soluble; STEBA Biotech, Luxembourg) is a form of tissue ablation that may be used therapeutically for localized prostate cancer (PCa). To study dosing parameters and associated treatment effects we undertook a prospective multicenter phase I/II trial of WST11 VTP for treatment of PCa METHODS: 30 men with unilateral, low volume, Gleason 3+3 PCa were enrolled at 5 centers following local IRB approval. Light energy, fiber number, and WST11 dose were escalated to identify optimal dosing parameters for VTP hemiablation. Men were treated by VTP and evaluated by post-treatment MRI and biopsy. PSA, light dose index (LDI -defined as sum of fiber length/ desired treatment volume), toxicity, and quality of life parameters were recorded. RESULTS: Following dose escalation, 21 men received optimized dosing of 4 mg/kg WST11 200 J energy. On post-treatment biopsy, residual PCa was found in the treated lobe in 10 men, untreated lobe in 4, and both lobes in 1. When LDI>/=1, at optimal dosing, (n=15), 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment, with optimal dose and LDI >/=1, had negative post-treatment biopsy. Minimal effects on urinary, sexual function, and overall quality of life, were observed. CONCLUSIONS: Hemiablation of the prostate with WST11 VTP was well-tolerated and resulted in negative biopsy in the treated lobe for the majority of men. Dosing parameters and LDI appear related to tissue response as determined by MRI and biopsy. These parameters may serve as the basis for further prospective studies.
PMCID:5483996
PMID: 27291652
ISSN: 1527-3792
CID: 2144932
Re: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer
Taneja, Samir S
PMID: 27597066
ISSN: 1527-3792
CID: 2263872
Re: Enzalutamide versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Taneja, Samir S
PMID: 27597064
ISSN: 1527-3792
CID: 2263852
Re: Expectant Management of Veterans with Early-Stage Prostate Cancer
Taneja, Samir S
PMID: 27597067
ISSN: 1527-3792
CID: 2263882
Integrating MRI for the diagnosis of prostate cancer
Moore, Caroline M; Taneja, Samir S
PURPOSE OF REVIEW: We review recent developments in prostate MRI for prostate cancer diagnosis. RECENT FINDINGS: Large series have strengthened the case for the use of MRI prior to subsequent biopsy to maximize the detection of clinically significant disease, and reduce the detection of clinically insignificant disease. This has effectively moved the discussion on from whether MRI is useful in prostate cancer detection to how best to use it, and at which time point. The Prostate Imaging- Reporting And Data System (PIRADS) group have published a second version of the PIRADS criteria for prostate MRI, covering acquisition, interpretation, and reporting both for clinical practice and data collection for research.There is debate about the commonly used and more prescriptive PIRADS system versus the less prescriptive systems based on overall clinical impression of clinically significant disease (e.g. Likert or simplified quantum scoring). Studies suggest that the Likert or simplified quantum scoring approach may outperform PIRADSv2. Published data are conflicting on whether software-assisted fusion of MRI lesions to ultrasound used at biopsy is more effective than visual registration by a trained operator. SUMMARY: The use of prostate MRI is increasing worldwide, and the debate now focuses on how best to use it to optimize the detection of clinically significant disease.
PMID: 27367259
ISSN: 1473-6586
CID: 2167182